Large-scale cluster randomised trial reveals effectiveness of Helicobacter pylori eradication for gastric cancer prevention

References

[1] BrayF, Laversanne M, SungH, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2] de MartelC, Georges D, BrayF, FerlayJ, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020; 8(2): e180-e190.

[3] YangL, Kartsonaki C, YaoP, et al. The relative and attributable risks of cardia and non-cardia gastric cancer associated with Helicobacter pylori infection in China: a case-cohort study. Lancet Public Health. 2021; 6(12): e888-e896.

[4] LiuZ, XuH, YouW, PanK, LiW. Helicobacter pylori eradication for primary prevention of gastric cancer: progresses and challenges. J Natl Cancer Cent. 2024; 4(4): 299-310.

[5] IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. 2014. IARC Working Group Reports. http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8

[6] PanKF, LiWQ, ZhangL, et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat Med. 2024; 30(11): 3250-3260.

[7] FordAC, YuanY, MoayyediP. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020; 69(12): 2113-2121.

[8] WangL, LiZ, TayCY, Marshall BJ, GuB. Multicentre, cross-sectional surveillance of Helicobacter pylori prevalence and antibiotic resistance to clarithromycin and levofloxacin in urban China using the string test coupled with quantitative PCR. Lancet Microbe. 2024; 5(6): e512-e513.

[9] HeF, WangS, ZhengR, et al. Trends of gastric cancer burdens attributable to risk factors in China from 2000 to 2050. Lancet Reg Health West Pac. 2024; 44: 101003.

[10] MalfertheinerP, Camargo MC, El-OmarE, et al. Helicobacter pylori infection. Nat Rev Dis Primers. 2023; 9(1): 19.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.